Development, Validation, and Application of a Scoring Model for Non-alcoholic Steatohepatitis

被引:0
|
作者
Xiao, Jinfeng [1 ]
Zhang, Xinxin [1 ]
Zhu, Chonggui [1 ]
Gu, Yian [1 ]
Sun, Longhao [2 ]
Liang, Xiaoyu [2 ]
He, Qing [1 ]
机构
[1] Tianjin Med Univ Gen Hosp, Dept Endocrinol & Metab, 154 Anshan Rd, Tianjin 300052, Peoples R China
[2] Tianjin Med Univ Gen Hosp, Dept Gen Surg, Tianjin 300052, Peoples R China
关键词
Non-alcoholic liver disease; Non-alcoholic steatohepatitis; Non-invasive score; Sleeve gastrectomy; FATTY LIVER-DISEASE; MORBIDLY OBESE SUBJECTS; BARIATRIC SURGERY; PREVALENCE; PREDICTORS; FIBROSIS; SPECTRUM; SYSTEM; FEATURES;
D O I
10.1007/s11695-023-06804-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose The aim of this study was to explore risk factors of NASH and then develop a non-invasive scoring model in Chinese patients with obesity. A scoring system was then applied to assess the effect of sleeve gastrectomy on NASH.Methods A total of 243 patients with obesity were included and divided into NASH group and non-NASH group according to the pathological results of liver biopsy. Logistic regression was used to determine risk factors of NASH. A scoring model was derived by risk factors of NASH. Then, postoperative follow-up was performed in 70 patients.Results Among the 243 patients, 118 (48.56%) patients showed NASH. Multivariate logistic regression identified aspartate aminotransferase (AST) (>21.50 IU/L), high-density lipoprotein cholesterol (HDL-C) (<1.155mmol/L), and homeostasis model assessment (HOMA-IR) (>9.368) as independent risk factors of NASH. The model included above risk factors showed a negative predictive value (NPV) of 70.38% in the low-risk category and a positive predictive value (PPV) of 85.71% in the high-risk category, with the area under the receiver operator curve (AUROC) of 0.737. Bariatric surgery resulted in a sharp decline in AST and HOMA-IR and a significant increase of HDL-C. The points of scoring model were improved at 6 months after surgery.Conclusion A non-invasive scoring model was derived by the risk factors of NASH included AST, HDL-C, and HOMA-IR and applied to the postoperative follow-up. After sleeve gastrectomy, the above risk factors and points of scoring model were significantly improved.
引用
收藏
页码:3246 / 3255
页数:10
相关论文
共 50 条
  • [1] Development, Validation, and Application of a Scoring Model for Non-alcoholic Steatohepatitis
    Jinfeng Xiao
    Xinxin Zhang
    Chonggui Zhu
    Yian Gu
    Longhao Sun
    Xiaoyu Liang
    Qing He
    [J]. Obesity Surgery, 2023, 33 : 3246 - 3255
  • [2] Towards the development of a scoring system for diagnosing Non-alcoholic Steatohepatitis (NASH).
    Khan, AR
    Riley, TR
    [J]. HEPATOLOGY, 2001, 34 (04) : 695A - 695A
  • [3] Design and validation of a histologic scoring system for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
    Kleiner, DE
    Brunt, EM
    Van Natta, ML
    Behling, C
    Contos, MJ
    Cummings, OW
    Ferrell, LD
    Liu, YC
    Torbenson, MS
    Yeh, M
    McCullough, AJ
    Sanyal, AJ
    [J]. HEPATOLOGY, 2003, 38 (04) : 233A - 233A
  • [4] A mouse model for Non-alcoholic Steatohepatitis
    Sundaresan, Sinju
    Vijayagopal, Parakat
    Mills, Nathaniel
    Imrhan, Victorine
    Prasad, Chandan
    [J]. FASEB JOURNAL, 2010, 24
  • [5] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, Sudeep
    Trembling, Paul M.
    Guha, Indra Neil
    Parkes, Julie
    Kaye, Philip
    Burt, Alastair D.
    Ryder, Stephen D.
    Aithal, Guruprasad P.
    Day, Christopher P.
    Rosenberg, William M.
    [J]. HEPATOLOGY, 2011, 54 : 1123A - 1123A
  • [6] VALIDATION OF A NOVEL BIOMARKER MODEL FOR THE PREDICTION OF NON-ALCOHOLIC STEATOHEPATITIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE
    Tanwar, S.
    Trembling, P.
    Guha, I. N.
    Parkes, J.
    Kaye, P.
    Burt, A. D.
    Ryder, S. D.
    Aithal, G. P.
    Day, C. P.
    Rosenberg, W. M.
    [J]. GUT, 2011, 60 : A4 - A5
  • [7] Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
    Morishita, Asahiro
    Tadokoro, Tomoko
    Fujihara, Shintaro
    Iwama, Hisakazu
    Oura, Kyoko
    Fujita, Koji
    Tani, Joji
    Takuma, Kei
    Nakahara, Mai
    Shi, Tingting
    Haba, Reiji
    Okano, Keiichi
    Nishiyama, Akira
    Ono, Masafumi
    Himoto, Takashi
    Masaki, Tsutomu
    [J]. PLOS ONE, 2022, 17 (02):
  • [8] Alcoholic and non-alcoholic steatohepatitis
    Neuman, Manuela G.
    French, Samuel W.
    French, Barbara A.
    Seitz, Helmut K.
    Cohen, Lawrence B.
    Mueller, Sebastian
    Osna, Natalia A.
    Kharbanda, Kusum K.
    Seth, Devanshi
    Bautista, Abraham
    Thompson, Kyle J.
    McKillop, Iain H.
    Kirpich, Irina A.
    McClain, Craig J.
    Bataller, Ramon
    Nanau, Radu M.
    Voiculescu, Mihai
    Opris, Mihai
    Shen, Hong
    Tillman, Brittany
    Li, Jun
    Liu, Hui
    Thomes, Paul G.
    Ganesan, Murali
    Malnick, Steve
    [J]. EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2014, 97 (03) : 492 - 510
  • [9] Alcoholic and non-alcoholic steatohepatitis
    不详
    [J]. PATHOLOGY RESEARCH AND PRACTICE, 2005, 201 (03) : 266 - 266
  • [10] DEVELOPMENT AND VALIDATION OF NASH DIAGNOSTIC INDEX AS A NON-INVASIVE MODEL FOR DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS (NASH)
    Younossi, Z. M.
    Otgonsuren, M.
    Hunt, S.
    Afendy, A.
    Goodman, Z.
    Fang, Y.
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 : S554 - S554